|
1
|
Zimmer L, Haydu LE, Menzies AM, Scolyer
RA, Kefford RF, Thompson JF, Schadendorf D and Long GV: Incidence
of new primary melanomas after diagnosis of stage III and IV
melanoma. J Clin Oncol. 32:816–823. 2014. View Article : Google Scholar
|
|
2
|
Arnold M, Holterhues C, Hollestein LM,
Coebergh JW, Nijsten T, Pukkala E, Holleczek B, Tryggvadóttir L,
Comber H, Bento MJ, et al: Trends in incidence and predictions of
cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol
Venereol. 28:1170–1178. 2014. View Article : Google Scholar
|
|
3
|
Yin H, Shao Y and Chen X: The effects of
CD147 on the cell proliferation, apoptosis, invasion, and
angiogenesis in glioma. Neurol Sci. 38:129–136. 2017. View Article : Google Scholar
|
|
4
|
Kuang YH, Chen X, Su J, Wu LS, Liao LQ, Li
D, Chen ZS and Kanekura T: RNA interference targeting the CD147
induces apoptosis of multi-drug resistant cancer cells related to
XIAP depletion. Cancer Lett. 276:189–195. 2009. View Article : Google Scholar
|
|
5
|
Xie W, Xie H, Liu F, Li W, Dan J, Mei Y,
Dan L, Xiao X, Li J and Chen X: Propranolol induces apoptosis of
human umbilical vein endothelial cells through downregulation of
CD147. Br J Dermatol. 168:739–748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao S, Kuang YH and Chen X:
Overexpression of CD147 inhibits Chinese Hamster Ovary cells
apoptosis due to inducing methotrexate efflux. J Dermatol. 39:170.
2012.
|
|
7
|
Yu JS and Cui W: Proliferation, survival
and metabolism: The role of PI3K/AKT/mTOR signalling in
pluripotency and cell fate determination. Development.
143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lian C, Guo Y, Zhang J, Chen X and Peng C:
Targeting CD147 is a Novel Strategy for Antitumor Therapy. Curr
Pharm Des. 23:4410–4421. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stocker H, Andjelkovic M, Oldham S,
Laffargue M, Wymann MP, Hemmings BA and Hafen E: Living with lethal
PIP3 levels: Viability of flies lacking PTEN restored by a PH
domain mutation in Akt/PKB. Science. 295:2088–2091. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abraham J: PI3K/AKT/mTOR pathway
inhibitors: The ideal combination partners for breast cancer
therapies? Expert Rev Anticancer Ther. 15:51–68. 2015. View Article : Google Scholar
|
|
11
|
Bucheit AD, Chen G, Siroy A, Tetzlaff M,
Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, et
al: Complete loss of PTEN protein expression correlates with
shorter time to brain metastasis and survival in stage IIIB/C
melanoma patients with BRAFV600 mutations. Clin Cancer Res.
20:5527–5536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong Y, Richards JA, Gupta R, Aung PP,
Emley A, Kluger Y, Dogra SK, Mahalingam M and Wajapeyee N: PTEN
functions as a melanoma tumor suppressor by promoting host immune
response. Oncogene. 33:4632–4642. 2014. View Article : Google Scholar
|
|
13
|
Zhang W and Fuller G: IGFBP2 as a brain
tumor oncogene. Cancer Biol Ther. 6:995–996. 2007.PubMed/NCBI
|
|
14
|
Sztefko K, Hodorowicz-Zaniewska D, Popiela
T and Richter P: IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile
subunit (ALS) in colorectal cancer patients before surgery and
during one year follow up in relation to age. Adv Med Sci.
54:51–58. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore LM, Holmes KM, Smith SM, Wu Y,
Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN and Zhang
W: IGFBP2 is a candidate biomarker for Ink4a-Arf status and a
therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA.
106:16675–16679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng W, Su J, Wu L, Yang D, Long T, Li D,
Kuang Y, Li J, Qi M, Zhang J, et al: CD147 promotes melanoma
progression through hypoxia-induced MMP2 activation. Curr Mol Med.
14:163–173. 2014. View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Chen X, Lin J, Kanekura T, Su J, Lin W,
Xie H, Wu Y, Li J, Chen M and Chang J: A small interfering
CD147-targeting RNA inhibited the proliferation, invasiveness, and
metastatic activity of malignant melanoma. Cancer Res.
66:11323–11330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Council NR: Guide for the Care and Use of
Laboratory Animals. The National Academies Press; Washington, DC:
1996
|
|
20
|
Su J, Gao T, Jiang M, Wu L, Zeng W, Zhao
S, Peng C and Chen X: CD147 silencing inhibits tumor growth by
suppressing glucose transport in melanoma. Oncotarget.
7:64778–64784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gou X, Tang X, Kong DK, He X, Gao X, Guo
N, Hu Z, Zhao Z and Chen Y: CD147 is increased in HCC cells under
starvation and reduces cell death through upregulating p-mTOR in
vitro. Apoptosis. 21:110–119. 2016. View Article : Google Scholar
|
|
22
|
Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q,
Yang JM and Xu ZD: Up-regulation of CD147 and matrix
metalloproteinase-2, -9 induced by P-glycoprotein substrates in
multidrug resistant breast cancer cells. Cancer Sci. 98:1767–1774.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zou W, Yang H, Hou X, Zhang W, Chen B and
Xin X: Inhibition of CD147 gene expression via RNA interference
reduces tumor cell invasion, tumorigenicity and increases
chemosensitivity to paclitaxel in HO-8910 pm cells. Cancer Lett.
248:211–218. 2007. View Article : Google Scholar
|
|
24
|
Chen H, Fok KL, Jiang X, Jiang J, Chen Z,
Gui Y, Chan HC and Cai Z: CD147 regulates apoptosis in mouse
spermatocytes but not spermatogonia. Hum Reprod. 27:1568–1576.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Fok KL, Cai Z, Chen H and Chan HC:
CD147 regulates extrinsic apoptosis in spermatocytes by modulating
NFκB signaling pathways. Oncotarget. 8:3132–3143. 2017.
|
|
26
|
Tang J, Guo YS, Zhang Y, Yu XL, Li L,
Huang W, Li Y, Chen B, Jiang JL and Chen ZN: CD147 induces UPR to
inhibit apoptosis and chemosensitivity by increasing the
transcription of Bip in hepatocellular carcinoma. Cell Death
Differ. 19:1779–1790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reynolds CM, Perry JK and Vickers MH:
Manipulation of the growth hormone-insulin-like growth factor
(GH-IGF) axis: A treatment strategy to reverse the effects of early
life developmental programming. Int J Mol Sci. 18:182017.
View Article : Google Scholar
|
|
28
|
Podlutsky A, Valcarcel-Ares MN, Yancey K,
Podlutskaya V, Nagykaldi E, Gautam T, Miller RA, Sonntag WE,
Csiszar A and Ungvari Z: The GH/IGF-1 axis in a critical period
early in life determines cellular DNA repair capacity by altering
transcriptional regulation of DNA repair-related genes:
Implications for the developmental origins of cancer. Geroscience.
39:147–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sehgal P, Kumar N, Praveen Kumar VR, Patil
S, Bhattacharya A, Vijaya Kumar M, Mukherjee G and Kondaiah P:
Regulation of protumorigenic pathways by insulin like growth factor
binding protein2 and its association along with β-catenin in breast
cancer lymph node metastasis. Mol Cancer. 12:632013. View Article : Google Scholar
|
|
30
|
Chua CY, Liu Y, Granberg KJ, Hu L,
Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller
GN, et al: IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Oncogene. 35:738–747. 2016. View Article : Google Scholar
|
|
31
|
Biernacka KM, Uzoh CC, Zeng L, Persad RA,
Bahl A, Gillatt D, Perks CM and Holly JM: Hyperglycaemia-induced
chemore-sistance of prostate cancer cells due to IGFBP2. Endocr
Relat Cancer. 20:741–751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu H, Goel V and Haluska FG: PTEN
signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen X, Xi G, Radhakrishnan Y and Clemmons
DR: PDK1 recruitment to the SHPS-1 signaling complex enhances
insulin-like growth factor-i-stimulated AKT activation and vascular
smooth muscle cell survival. J Biol Chem. 285:29416–29424. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harris TK: PDK1 and PKB/Akt: Ideal targets
for development of new strategies to structure-based drug design.
IUBMB Life. 55:117–126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Wang SJ, Han ZH, Li YQ, Xue JH,
Gao DF, Wu XS and Wang CX: PI3K/AKT signaling pathway plays a role
in enhancement of eNOS activity by recombinant human angiotensin
converting enzyme 2 in human umbilical vein endothelial cells. Int
J Clin Exp Pathol. 7:8112–8117. 2014.
|
|
36
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goschzik T, Gessi M, Denkhaus D and
Pietsch T: PTEN mutations and activation of the PI3K/Akt/mTOR
signaling pathway in papillary tumors of the pineal region. J
Neuropathol Exp Neurol. 73:747–751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lv D, Liu J, Guo L, Wu D, Matsumoto K and
Huang L: PRAS40 deregulates apoptosis in Ewing sarcoma family
tumors by enhancing the insulin receptor/Akt and mTOR signaling
pathways. Am J Cancer Res. 6:486–497. 2016.PubMed/NCBI
|
|
39
|
Havel JJ, Li Z, Cheng D, Peng J and Fu H:
Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the
RPL11-HDM2-p53 nucleolar stress response pathway. Oncogene.
34:1487–1498. 2015. View Article : Google Scholar
|
|
40
|
Bhattacharya K, Maiti S and Mandal C: PTEN
negatively regulates mTORC2 formation and signaling in grade IV
glioma via Rictor hyperphosphorylation at Thr1135 and direct the
mode of action of an mTORC1/2 inhibitor. Oncogenesis. 5:e2272016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mehrian-Shai R, Chen CD, Shi T, Horvath S,
Nelson SF, Reichardt JK and Sawyers CL: Insulin growth
factor-binding protein 2 is a candidate biomarker for PTEN status
and PI3K/Akt pathway activation in glioblastoma and prostate
cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ahani N, Karimi Arzenani M, Shirkoohi R,
Rokouei M, Alipour Eskandani M and Nikravesh A: Expression of
insulin-like growth factor binding protein-2 (IGFBP-2) gene in
negative and positive human cytomegalovirus glioblastoma multiforme
tissues. Med Oncol. 31:8122014. View Article : Google Scholar
|
|
43
|
Mireuta M, Darnel A and Pollak M: IGFBP-2
expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway
through Sp1-induced increase in transcription. Growth Factors.
28:243–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
